title: Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma.
abstract: Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially for those with progressive disease and for those who experience treatment failure. Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has been approved for the treatment of patients with low- or intermediate-grade advanced pNET. In the randomized phase III RADIANT-3 study in patients with low- or intermediate-grade advanced pNET, everolimus significantly increased progression-free survival (PFS) and decreased the relative risk for disease progression by 65% over placebo. This case report describes a heavily pretreated patient with high-grade pNET and liver and peritoneal metastases who achieved prolonged PFS, clinically relevant partial radiologic tumor response, and resolution of constitutional symptoms with improvement in Karnofsky performance status while receiving a combination of everolimus and octreotide long-acting repeatable (LAR). Radiologic and clinical responses were maintained for 19 months, with minimal toxicity over the course of treatment. This case supports the findings that the combination of everolimus plus octreotide LAR may be considered for use in patients with high-grade pNET and progressive disease. Although behavior and aggressiveness are different between low- or intermediate-grade and high-grade pNET, some high-grade pNET may express mTOR; hence, everolimus should be considered in a clinical trial.
authors.affiliation: Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Paula J
authors.initials: PJ
authors.lastname: Fonseca
authors.forename: Esther
authors.initials: E
authors.lastname: Uriol
authors.forename: José A
authors.initials: JA
authors.lastname: Galván
authors.forename: Carlos
authors.initials: C
authors.lastname: Alvarez
authors.forename: Quionia
authors.initials: Q
authors.lastname: Pérez
authors.forename: Noemi
authors.initials: N
authors.lastname: Villanueva
authors.forename: José P
authors.initials: JP
authors.lastname: Berros
authors.forename: Marta
authors.initials: M
authors.lastname: Izquierdo
authors.forename: José M
authors.initials: JM
authors.lastname: Viéitez
keywords: Everolimus; Neuroendocrine tumors; Octreotide long-acting repeatable; Pancreatic
references.citation: N Engl J Med. 2011 Feb 10;364(6):514-23
references.pmid: 21306238
references.citation: Neuroendocrinology. 2009;90(2):214-9
references.pmid: 19713713
references.citation: Target Oncol. 2011 Jun;6(2):65-8
references.pmid: 21468754
references.citation: Ann Surg Oncol. 2007 Dec;14(12):3492-500
references.pmid: 17896148
references.citation: Cancer Chemother Pharmacol. 2010 Apr;65(5):889-93
references.pmid: 19657638
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v223-7
references.pmid: 20555086
references.citation: J Hematol Oncol. 2011 Jun 14;4:29
references.pmid: 21672194
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4656-63
references.pmid: 19704057
references.citation: Cancer. 2011 Jan 15;117(2):268-75
references.pmid: 20824724
references.citation: J Clin Oncol. 2008 Jun 20;26(18):3063-72
references.pmid: 18565894
references.citation: Pancreas. 2010 Aug;39(6):799-800
references.pmid: 20664477
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4762-71
references.pmid: 15570077
references.citation: J Clin Oncol. 2008 Sep 10;26(26):4311-8
references.pmid: 18779618
references.citation: Eur J Cancer. 2004 Mar;40(4):515-20
references.pmid: 14962717
references.citation: Lancet. 2011 Dec 10;378(9808):2005-2012
references.pmid: 22119496